Description

Energoton (Trimetazidine Dihydrochloride) Coated Tablets 0.02 g. №60

Ingredients

Active ingredient: Trimetazidine dihydrochloride 0.02 g per coated tablet.

Dosage

Dosage: The usual dose is 1 tablet three times a day, preferably taken with meals.

Indications

Indications: Energoton tablets are indicated for the symptomatic treatment of stable angina pectoris.

Contraindications

Contraindications: Do not use Energoton tablets in patients with Parkinson’s disease, tremors, or hyperthyroidism.

Directions

Directions: Swallow the tablet whole with a glass of water. Do not crush or chew the tablet.

Pharmacological Properties

Pharmacological Effects: Trimetazidine acts by shifting myocardial metabolism from fatty acid oxidation to glucose oxidation, thereby preserving energy production in the ischemic myocardium. This results in improved cardiac function and reduced ischemic damage.

Side Effects

Common side effects of Energoton may include nausea, vomiting, and headache. If any of these effects persist or worsen, inform your doctor promptly.

Usage Instructions

For optimal results, follow the prescribed dosage regimen strictly. Do not alter the dosage without consulting your healthcare provider.

Benefits Compared to Analogues

Energoton has shown superior efficacy in improving exercise tolerance and reducing angina symptoms compared to traditional therapies.

Suitable Patient Groups

Energoton is suitable for adult patients with stable angina pectoris. It is not recommended for use in children, pregnant women, or individuals with severe liver impairment.

Storage and Shelf Life

Store Energoton in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use the product if expired.

Packaging Description

Energoton is packaged in blister packs containing 60 coated tablets. Each tablet is individually sealed for protection.

Clinical Evidence and Proven Effectiveness

Energoton (trimetazidine dihydrochloride) has been extensively studied for its efficacy in the treatment of angina pectoris. Clinical trials have shown that trimetazidine improves exercise tolerance, reduces the frequency of angina attacks, and enhances the quality of life in patients with stable angina.